Sugi Predict

Sugi Predict / Compounds / Tasquinimod

Tasquinimod

Tasquinimod

SCHEMBL4476895

COc1cccc2c1c(O)c(C(=O)N(C)c1ccc(C(F)(F)F)cc1)c(=O)n2C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HDAC4 P56524 1/20 1.00
▸ MEN1 O00255 2/20 0.50
▸ KMT2A Q03164 2/20 0.50
▸ PGR P06401 1/20 0.50
▸ POLB P06746 2/20 0.39
▸ RXFP1 Q9HBX9 1/20 0.38
▸ GPR139 Q6DWJ6 1/20 0.37
▸ TLR7 Q9NYK1 1/20 0.37
▸ GPBAR1 Q8TDU6 2/20 0.37
▸ SRC P12931 1/20 0.36
▸ SGMS2 Q8NHU3 5/20 0.36
▸ MCHR1 Q99705 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ SGMS1 Q86VZ5 2/20 0.35
▸ PABPC1 P11940 1/20 0.35
▸ TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tasquinimod SCHEMBL29362522 1.00 HDAC4 (1.00) HDAC4MEN1KMT2APGRPOLB
Tasquinimod SCHEMBL14312101 0.93 HDAC4 (0.87) HDAC4MEN1KMT2APGRPOLB
SCHEMBL18416042 0.93 HDAC4 (0.87) HDAC4MEN1KMT2APGRPOLB
SCHEMBL26552824 0.90 HDAC4 (0.82) HDAC4MEN1KMT2APGRPOLB
SCHEMBL19398184 0.89 HDAC4 (0.79) HDAC4MEN1KMT2APGRPOLB
SCHEMBL7003940 0.88 HDAC4 (0.79) HDAC4MEN1KMT2APGRPOLB
SCHEMBL14376051 0.88 HDAC4 (0.78) HDAC4MEN1KMT2APGRTLR7
SCHEMBL6999887 0.87 HDAC4 (0.78) HDAC4MEN1KMT2APGRPOLB
SCHEMBL7093123 0.87 HDAC4 (0.78) HDAC4MEN1KMT2APGRPOLB
SCHEMBL6994317 0.87 HDAC4 (0.77) HDAC4MEN1KMT2APGRPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1413 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125650-A1 METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES TRAILHEAD BIOSYSTEMS INC (US) 2026-05-07 — — US claimed
EP-4735045-A2 OXAZAPHOSPHORINE ANTIBODY DRUG CONJUGATES AND METHODS OF USE La Life Products, LLC (US) 2026-05-06 — — EP claimed
EP-4732908-A2 CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS Biomed Valley Discoveries, Inc. (US) 2026-04-29 — — EP claimed
EP-4720316-A2 NON-VIRAL CELL ENGINEERING Arsenal Biosciences, Inc. (US) 2026-04-08 — — EP claimed
US-12582643-B2 Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy ACTIVE BIOTECH AB (SE) 2026-03-24 — — US claimed
US-20260076908-A1 PLURALITY OF TASQUINIMOD PARTICLES AND USE THEREOF ACTIVE BIOTECH AB (SE) 2026-03-19 — — US claimed
EP-4043017-B1 CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS BIOMED VALLEY DISCOVERIES INC (US) 2026-01-28 — — EP claimed
EP-4062917-B1 CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS BIOMED VALLEY DISCOVERIES INC (US) 2025-12-03 — — EP claimed
US-12485095-B2 Plurality of tasquinimod particles and use thereof ACTIVE BIOTECH AB (SE) 2025-12-02 — — US claimed
WO-2025228998-A1 USE OF HDAC4 INHIBITORS FOR THE TREATMENT OF MELANOMA Institut National de la Santé et de la Recherche Médicale (FR) 2025-11-06 — — WO claimed
EP-1511732-B1 PROCESS FOR THE MANUFACTURE OF QUINOLINE DERIVATIVES ACTIVE BIOTECH AB (SE) 2006-12-20 — — EP claimed
US-6875869-B2 Process for the manufacture of quinoline derivatives ACTIVE BIOTECH AB (SE) 2005-04-05 — — US claimed
US-20040034227-A1 Process for the manufacture of quinoline derivatives ACTIVE BIOTECH AB (SE) 2004-02-19 — — US claimed
EP-1095021-B1 QUINOLINE DERIVATIVES ACTIVE BIOTECH AB (SE) 2003-09-17 — — EP claimed
EP-1224172-A1 DRUGS FOR THE TREATMENT OF MALIGNANT TUMOURS Active Biotech AB (SE) 2002-07-24 — — EP claimed
US-6395750-B1 Includes laquinimod, N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxo-quinoline-3-carboxamide and its salts; breat or prostate cancer ACTIVE BIOTECH AB (SE) 2002-05-28 — — US claimed
WO-2001030758-A1 DRUGS FOR THE TREATMENT OF MALIGNANT TUMOURS ACTIVE BIOTECH AB (SE) 2001-05-03 — — WO claimed
EP-1095021-A1 QUINOLINE DERIVATIVES Active Biotech AB (SE) 2001-05-02 — — EP claimed
US-6133285-A 1-METHYL-2-OXO-3-N-PHENYL-N-METHYLAMINOCARBONYL-4-HYDROXY-1,2 -DIHYDRO-QUINOLINES; AUTOIMMUNE DISEASE AND PATHOLOGICAL INFLAMMATION, E.G., ASTHMA, ATHEROSCLEROSIS, STROKE AND ALZHEIMER'S DISEASE AND, ESPECIALLY, MULTIPLE SCLEROSIS ACTIVE BIOTECH AB (SE) 2000-10-17 — — US claimed
WO-2000003991-A1 QUINOLINE DERIVATIVES ACTIVE BIOTECH AB (SE) 2000-01-27 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12582643-B2 Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy PSMB4, PSMB2, MYD88 HDAC4 102/4885MEN1 1021/4885KMT2A 214/4885
US-20260076908-A1 PLURALITY OF TASQUINIMOD PARTICLES AND USE THEREOF JAK2, MYD88, TLR9 HDAC4 559/4885MEN1 2734/4885KMT2A 260/4885
US-20040034227-A1 Process for the manufacture of quinoline derivatives CYP4F3, HTR3C, CYP3A43 HDAC4 4842/4885MEN1 2749/4885KMT2A 2359/4885
US-20260125650-A1 METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES WNT3A, GSK3B, GSK3A HDAC4 27/4885MEN1 4529/4885KMT2A 1758/4885
US-12485095-B2 Plurality of tasquinimod particles and use thereof TLR9, POLQ, TLR7 HDAC4 517/4885MEN1 1848/4885KMT2A 1068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.